<DOC>
	<DOCNO>NCT01843127</DOCNO>
	<brief_summary>To explore mechanism action ranolazine potential treatment type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Ranolazine Postprandial Glucagon Subjects With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Males female , 18 65 year old , inclusive Documented history T2DM ≥5 year Body mass index ( BMI ) 20.0 40.0 kg/m2 , inclusive , Screening Stable treatment ( ≥ 12 week ) metformin alone , sulfonylurea alone , meglitinide alone , combination metformin either sulfonylurea meglitinide HbA1c ≥ 7.0 % ≤ 10.5 % , inclusive , Screening Fasting glucose within specific range , Screening 14 +/2 day washout prior oral antidiabetic agent Fasting serum Cpeptide ≥0.8 ng/mL , Screening Estimated glomerular filtration rate ( eGFR ) ≥60 mL/min/1.73 m2 Ability willingness comply study procedure course study , include washout oral antidiabetic ( OAD ) agents approximately 2 week prior Day 2 admission Females childbearing potential must negative pregnancy test Screening Day 2 admission must agree use highly effective contraception method Screening throughout study participation 14 day follow last dose study drug . History type 1 diabetes mellitus secondary form diabetes History acute diabetes complication Recent significant heart condition Uncontrolled hypertension QTc interval &gt; 500 msec ECG Screening Day 2 admission , personal family history QTc prolongation , congenital long QT syndrome , use drug prolong QTc interval , Class Ia Class III antiarrhythmic agent , erythromycin , certain antipsychotic ( eg , ziprasidone ) History severe GI disease ( e.g. , gastroparesis ) History pancreatitis ( acute chronic ) Current consumption &gt; 14 alcoholic drink per week , 4 alcoholic drink one day Current regular use tobacco nicotinecontaining product excess 10 cigarette per day equivalent History substance abuse within 12 month prior Screening Significant hepatic disease , include , limited , chronic active hepatitis liver cirrhosis ( ChildPugh Class A , B , C ) History malignancy within 5 year prior Screening Significant thyroid disease Treatment select medication , indicate protocol Prior treatment openlabel ranolazine know hypersensitivity intolerance ranolazine excipients Known hypersensitivity intolerance GLP1 mimetics Known hypersensitivity intolerance acetaminophen Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 X upper limit normal ( ULN ) Total Bilirubin ( TB ) &gt; 2 mg/dL Hemoglobin &lt; 12 g/dL ( male ) &lt; 11 g/dL ( female ) Positive hepatitis B surface antigen Positive antihepatitis C virus antibody Positive human immunodeficiency virus1 ( HIV1 ) antibody Positive urine drug screen Positive alcohol test Donation blood blood product blood bank , blood transfusion , participation clinical study require withdrawal &gt; 500 mL blood 6 week prior Screening Females pregnant breastfeed Other condition ( ) , opinion investigator , would compromise safety subject , would prevent compliance study protocol , would compromise quality clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>